Identification of Clinical Candidate M2698, a Dual p70S6K and Akt Inhibitor, for Treatment of PAM Pathway-Altered Cancers

MLA

Brian H. Heasley, et al. “Identification of Clinical Candidate M2698, a Dual P70S6K and Akt Inhibitor, for Treatment of PAM Pathway-Altered Cancers.” Journal of Medicinal Chemistry, vol. 64, Oct. 2021, pp. 14603–19. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....6f0f668e1b7d0d3fdf120a40211a6894&authtype=sso&custid=ns315887.

APA

Brian H. Heasley, Jing Lin, Thomas F. N. Haxell, Igor Mochalkin, Constantin Neagu, Felix Rohdich, Ruoxi Lan, Amanda E. Sutton, Jennifer Jackson, Potnick Justin, Bayard R. Huck, Andreas Machl, Katrin Georgi, Xiaoling Chen, Sherer Brian A, Erik Wilker, Thomas E. Richardson, Anderson Clark, Reinaldo Jones, … Lindsey Crowley. (2021). Identification of Clinical Candidate M2698, a Dual p70S6K and Akt Inhibitor, for Treatment of PAM Pathway-Altered Cancers. Journal of Medicinal Chemistry, 64, 14603–14619.

Chicago

Brian H. Heasley, Jing Lin, Thomas F. N. Haxell, Igor Mochalkin, Constantin Neagu, Felix Rohdich, Ruoxi Lan, et al. 2021. “Identification of Clinical Candidate M2698, a Dual P70S6K and Akt Inhibitor, for Treatment of PAM Pathway-Altered Cancers.” Journal of Medicinal Chemistry 64 (October): 14603–19. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....6f0f668e1b7d0d3fdf120a40211a6894&authtype=sso&custid=ns315887.